文献速递炎症性肠病

硫嘌呤维持单药治疗炎症性肠病中实验室监测的附加价值有限

Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-28

该回顾性分析纳入1132例已接受至少12个月硫嘌呤单药治疗的成人IBD患者,评估维持期实验室毒性发生率及临床后果。中位随访3.3年,仅0.7%的实验室评估导致治疗调整,每治疗年调整风险1.9%;严重实验室毒性罕见,监测未能预防治疗相关并发症。结论认为治疗1年后实验室监测间隔可延长至超过4个月。

要点

  • 硫嘌呤维持治疗1年后严重实验室毒性罕见,每治疗年骨髓毒性7.1%、肝毒性5.1%。
  • 仅0.7%的实验室评估导致治疗调整,每治疗年调整风险1.9%。
  • 监测未能预防治疗相关并发症,1年后可考虑延长监测间隔至超过4个月。

核心结论

  • 硫嘌呤单药治疗1年后严重实验室毒性不常见,监测间隔为4个月时仍如此。
  • 发现实验室毒性后治疗调整罕见,监测未能预防治疗相关并发症。
  • 治疗1年后实验室监测间隔可降低至超过4个月。

研究设计与样本

  • 回顾性分析2000至2016年成人IBD患者,已连续接受12个月硫嘌呤单药治疗(基线)。
  • 共1132例患者(56%女性,74%使用硫嘌呤),中位随访3.3年,完成12391次实验室评估。
  • 中位监测频率为每治疗年3.1次评估。

主要发现

  • 仅83/12391(0.7%)次评估导致治疗调整:46例减量、28例停药、9例加用别嘌醇。
  • 每治疗年治疗调整风险为1.9%。
  • 骨髓毒性发生率为每治疗年7.1%(轻度5.1%、中度1.8%、重度0.1%)。
  • 肝毒性发生率为每治疗年5.1%(轻度3.8%、中度1.1%、重度0.2%)。
  • 12例(1.1%)患者发生治疗相关并发症并伴实验室毒性,监测未能预防。

关键数值与推荐

  • 骨髓毒性定义:白细胞计数<4.0×10e9/L和/或血小板计数<150×10e9/L。
  • 肝毒性定义:GGT、AP、ALT和/或AST高于正常上限,排除孤立性AST/AP升高。

临床怎么用

  • 对于已接受硫嘌呤单药治疗至少1年的IBD患者,可考虑将实验室监测间隔延长至超过4个月。
  • 延长监测间隔前应评估患者个体风险,并告知监测可能无法预防所有治疗相关并发症。

局限性

  • 回顾性分析设计可能影响数据完整性。
  • 仅纳入已耐受12个月硫嘌呤单药治疗的患者,结论不适用于治疗初期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To timely detect myelotoxicity and hepatotoxicity, laboratory monitoring at 3-month intervals is advised throughout thiopurine maintenance treatment for IBD. However, reported incidence rates of myelotoxicity and hepatotoxicity in maintenance treatment are low. AIM: To assess incidence rates and clinical consequences of myelotoxicity and hepatotoxicity in thiopurine maintenance therapy after at least 1 year of thiopurine treatment. METHODS: Retrospective analysis of therapy adjustment for laboratory toxicity in adult IBD patients after 12 consecutive months of azathioprine (AZA) or mercaptopurine monotherapy (ie baseline) between 2000 and 2016. Incidence rates of laboratory toxicity (ie myelotoxicity [leucocyte count <4.0 × 10e9/L, and/or platelet count <150 × 10e9/L] and/or hepatotoxicity (gamma-glutamyltransferase [GGT], alkaline phosphatase [AP], ALT and/or AST above ULN, excluding isolated increased AST/AP]) and associated diagnostic procedures and complications were assessed. RESULTS: In total, 12,391 laboratory assessments were performed on 1132 patients (56% female, AZA 74%) during 3.3 years of median follow-up. Median monitoring frequency was 3.1 assessments/treatment year. Only 83/12,391 (0.7%) assessments resulted in therapy adjustment, dose reduction in 46 patients, cessation in 28 and allopurinol initiation in nine; risk of therapy adjustment was 1.9% per treatment year. Incidence rates of myelotoxicity were 7.1% (5.1% mild/1.8% moderate/0.1% severe) and hepatotoxicity 5.1% (3.8% mild/1.1% moderate/0.2% severe) per treatment year. Treatment-related complications with concurrent laboratory toxicity occurred in 12 patients (1.1%) and would not have been prevented by monitoring. CONCLUSION: Severe laboratory toxicity is uncommon after 1 year of thiopurine monotherapy at 4-month monitoring intervals. Therapy adjustments are rare after detection of laboratory toxicity. After 1 year of thiopurine monotherapy, laboratory monitoring may be lowered to less than a 4-month interval.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kreijne JE, de Vries AC, de Veer RC, et al. Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2020. PMID: 32342997. doi:10.1111/apt.15734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。